BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Name: BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
License: Public Domain

AstraZeneca

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

type-2-diabetes

type 2 diabetes

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 126075
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.